Skip to content

GUDUCHI RASAYANA (GILOY) FOR HYPOTHYROIDISM PATIENTS

EFFECT OF GUDUCHI RASAYANA IN THE MANAGEMENT OF MEDOROGA ASSOCIATED WITH HYPOTHYROIDISM

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/01/030461
Enrollment
31
Registered
2021-01-14
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E039- Hypothyroidism, unspecified

Interventions

Intervention1: GUDUCHI RASAYANA: 1)TRIVRITA AVALEHA 15 G ONCE DAILY IN MORNING ORALLY EMPTY STOMACH WITH WARM WATER FOR 3 DAYS. 2)GUDUCHI GHAN VATI 4 TAB ON 1ST DAY, 8 TAB ON 2ND DAY,12 TAB ON 3RD DAY

Sponsors

ALL INDIA INSTITUTE OF AYURVEDA
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1)Age- 18-60 years. 2)Patients of both sexes. 3)TSH levels greater than/equal to 4.6 mIU/L to greater than/equal to 19.9 mIU/L with or without thyroxine. 4)Patients having clinical symptoms of Medoroga like- Ashakta sarvakarmasu,kshudra shwasa, trisha ,moha, Swapna, kathana sadana ,kshudha, sweda , daurgandhya, alpa prana, alpa maithuna, udara vriddhi etc. 5)Patients having clinical symptoms of hypothyroidism like - Weakness, Fatigue, Muscle ache, Muscle weakness, Breathlessness, Lethargy, Hoarseness of voice, loss of libido, Menstrual abnormality, Puffiness of the face and eyelids, Peripheral edema, Weight gain, Dry coarse skin, Constipation, Hair loss, Feeling cold.

Exclusion criteria

Exclusion criteria: 1)Patient having TSH level greater than 19.9 mIU/ L. 2)Recent thyroid surgery or radio-iodine (within 12 months). 3)Uncontrolled blood sugar, hypertension. 4)Prior clinical diagnosis of dementia. 5)Recent acute coronary syndrome, including myocardial infarction or unstable angina. 6)Plan to move out of the region in which the trial is being conducted within the next 2 years (proposed minimum time of study) 7)Suffering from diseases like HIV, tuberculosis, encephalopathy, goiter, other endocrine disorders and other autoimmune disorders. 8)Pregnancy, lactation. 9)Any other condition/medication which interfere with the intervention.

Design outcomes

Primary

MeasureTime frame
1)Change in symptoms of Medoroga. 2)Change in serum TSH levels. 3)Change in symptoms of hypothyroidism and Fatigue symptoms.Timepoint: 0th day, 18th day, 33rd day, follow up after completion of study.

Secondary

MeasureTime frame
Overall improvement in health-related quality of life.Timepoint: 0th day, 18th day, 33rd day, follow up after completion of study.

Countries

India

Contacts

Public ContactDr V G Huddar

All India Institute of Ayurveda

drvghuddar@gmail.com9986697942

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026